5 Questions for the New Chair of NICE Sharmila Nebhrajani
S. Nebharajani assumed the role of chair of NICE in May 2020, most recently serving as CEO of Wilton Park, [...]
Former FDA Commish Califf: Weighing the Benefits & Risks of the Growing Number of Observational Treatment Assessments
In a recently published JAMA Viewpoint, former FDA Commissioner Robert Califf and colleagues mused about a growing concern about inferring [...]
Trump v. Pharma: a “Kinda Sorta” War
Politico summarizes Trump's "kinda sorta" war with pharma, kicked off last week with presidential tweets about "nasty" drug ads that [...]
Unsupported Price Hikes: Drug manufacturers will be penalized in NASHP’s new model bill
The National Academy for State Health Policy’s (NASHP) newly introduced model law, an Act to Protect Consumers from Unsupported Price Increases [...]
Medicare turns 55, and now’s the time to look at Part D – did it work?
On July 30, 1965, President Lyndon B. Johnson signed into law legislation that established the Medicare and Medicaid programs. The [...]
New Data Released: Higher cost-sharing for brand medicines experienced by commercially insured patients
Health plans are increasingly using deductibles and coinsurance to shift more of the cost of care to chronically ill patients [...]
Payers probably won’t pass COVID savings onto members, despite pandemic-driven boon
Payers were prepared for skyrocketing medical costs due to COVID, but the opposite happened: people consumed less healthcare, on average. [...]
Not interested: Pharma execs refuse White House meeting over drug pricing executive orders
Trump's recent executive orders linking drug prices in Medicare to lower prices abroad caused a significant rift with the pharma [...]
High-Value Care Every Time: Recommendations From The National Quality Task Force
To address the high-cost, low-value healthcare dilemma in the United States, the National Quality Forum (NQF) launched the National Quality [...]
Cytel Scientists Call for a “Statistician-First Workflow” to Optimize Drug Development
Adaptive trial designs within oncology are described by Cytel scientists, and address data, statistical, and commercial and scientific value of [...]
Incorporating Value-based Care Into Oncology
Value-based care within insurance design utilizes evidence-based medicine to distinguish high-value and low-value diagnostics and treatments. The goals of value-based [...]
Viewpoint in JAMA: Integrating Personalized Medicine with Population Health Management: The Path Forward
In this viewpoint article published in the Journal of the American Medical Association, the authors posit that genome-wide DNA sequencing [...]
A Military-Civilian Perspective on Real-World Evidence to Support Regulatory Decision Making
This article summarizes how the US Military Health System (MHS) used real-world data (RWD) during the Iraq and Afghanistan Wars [...]
New Report: Provider Perceptions of Value-Based Care
Provider Perceptions of Value-Based Care aimed to understand provider views on value-based care and their partnership with private and public [...]
BresMed White Paper: 8 Common Challenges with Rare Disease Drug Value and How to Address Them
BresMed, and international HEOR consultancy, developed a white paper exploring eight key challenges that manufacturers face when demonstrating the value [...]
Dread Expressed by Public Health Experts on Hurried FDA Signoff on COVID-19 Vaccine
Eighty-nine sites are enrolling patients in the landmark Phase 3 trial for Moderna Therapeutics vaccine kicked off on Monday, July [...]
New Platform for Affordable Genomic Cancer Profiling Launched
A next-generation sequencing reference laboratory will use artificial intelligence (AI) to advance precision medicine to determine genomic signatures, first for [...]
What Do Trump’s Drug Pricing Orders Mean, Other than Confusion?
Consistent with the status quo chaos that surrounds the White House, the Trump Administration's four drug pricing executive orders unveiled [...]
Lilly Partners with Prime Therapeutics: How Next Generation Value-based Arrangements Put Patients First
Value-based arrangements (VBA) are increasingly used, although most medicines are paid based on volume of product purchased or cost per [...]
Going on Now! AcademyHealth 2020 is Virtual Yet Vital: Here’s Why
Kicking off today, AcademyHealth 2020 will provide vital insights over a 2-week period from July 28 – August 6 with [...]
Showdown: White House Cancels Pharma Meeting on International Pricing
On Tuesday, July 28, the White House abruptly canceled a meeting with drug company executives to discuss the most favored [...]
Applications Sought for AMCP Board; Deadline is September 2
AMCP is seeking board members for the position of president-elect, treasurer, and two directors. Qualified candidates will possess the following competencies: [...]
Tufts Analyzes Cost-Effectiveness Analysis for 1974-2018
Kim et. al. of Tufts Medical Center published an examination in the journal Pharmacoeconomics assessing CEA and Global Health CEA [...]
ISPOR Offering Course on Causal Inference in Observational, Pragmatic Trials
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is offering a 4-hour course on causal inference in observational data [...]
IFAPP, MAPS Course Offers Certificate in Medicine Development
An online course hosted by IFAPP Academy in partnership with the Medical Affairs Professional Society (MAPS) aims to give medical [...]